vs
Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
La Rosa Holdings Corp. is the larger business by last-quarter revenue ($20.2M vs $18.6M, roughly 1.1× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -27.4%, a 93.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 3.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 72.5%).
V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
LRHC vs SCYX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.2M | $18.6M |
| Net Profit | $-5.5M | $12.3M |
| Gross Margin | 8.4% | — |
| Operating Margin | -24.7% | 56.3% |
| Net Margin | -27.4% | 65.7% |
| Revenue YoY | 3.2% | 1808.5% |
| Net Profit YoY | -125.7% | 376.5% |
| EPS (diluted) | $-5.44 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | $20.2M | $334.0K | ||
| Q2 25 | $23.2M | $1.4M | ||
| Q1 25 | $17.5M | $257.0K | ||
| Q4 24 | $17.7M | $977.0K | ||
| Q3 24 | $19.6M | $660.0K | ||
| Q2 24 | $19.1M | $736.0K | ||
| Q1 24 | $13.1M | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $-5.5M | $-8.6M | ||
| Q2 25 | $78.4M | $-6.9M | ||
| Q1 25 | $-95.7M | $-5.4M | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $-2.5M | $-2.8M | ||
| Q2 24 | $-2.3M | $-14.5M | ||
| Q1 24 | $-4.6M | $411.0K |
| Q4 25 | — | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 8.9% | — |
| Q4 25 | — | 56.3% | ||
| Q3 25 | -24.7% | -2516.5% | ||
| Q2 25 | -10.6% | -701.0% | ||
| Q1 25 | -26.7% | -3350.2% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -8.9% | -1563.6% | ||
| Q2 24 | -9.7% | -1255.0% | ||
| Q1 24 | -35.0% | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | -27.4% | -2572.2% | ||
| Q2 25 | 337.8% | -504.8% | ||
| Q1 25 | -546.5% | -2097.7% | ||
| Q4 24 | -28.7% | — | ||
| Q3 24 | -12.5% | -425.5% | ||
| Q2 24 | -12.2% | -1964.4% | ||
| Q1 24 | -35.1% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | $-5.44 | $-0.17 | ||
| Q2 25 | $15.25 | $-0.14 | ||
| Q1 25 | $-5.86 | $-0.11 | ||
| Q4 24 | $28.54 | — | ||
| Q3 24 | $-16.49 | $-0.06 | ||
| Q2 24 | $-12.49 | $-0.30 | ||
| Q1 24 | $-0.35 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.0M | $40.0M |
| Total DebtLower is stronger | $642.8K | — |
| Stockholders' EquityBook value | $1.6M | $49.4M |
| Total Assets | $21.7M | $59.0M |
| Debt / EquityLower = less leverage | 0.41× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | $4.0M | $37.9M | ||
| Q2 25 | $5.1M | $44.8M | ||
| Q1 25 | $2.9M | $40.6M | ||
| Q4 24 | $1.4M | $59.3M | ||
| Q3 24 | $1.8M | $68.8M | ||
| Q2 24 | $1.6M | $73.0M | ||
| Q1 24 | $1.1M | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | $642.8K | — | ||
| Q2 25 | $644.3K | — | ||
| Q1 25 | $645.9K | — | ||
| Q4 24 | $647.6K | — | ||
| Q3 24 | $649.2K | — | ||
| Q2 24 | $650.8K | — | ||
| Q1 24 | $652.4K | — |
| Q4 25 | — | $49.4M | ||
| Q3 25 | $1.6M | $36.4M | ||
| Q2 25 | $3.4M | $44.5M | ||
| Q1 25 | $-87.5M | $50.5M | ||
| Q4 24 | $2.6M | $55.1M | ||
| Q3 24 | $5.0M | $58.5M | ||
| Q2 24 | $4.7M | $60.4M | ||
| Q1 24 | $5.6M | $74.1M |
| Q4 25 | — | $59.0M | ||
| Q3 25 | $21.7M | $51.1M | ||
| Q2 25 | $22.9M | $60.7M | ||
| Q1 25 | $21.0M | $67.9M | ||
| Q4 24 | $19.4M | $90.6M | ||
| Q3 24 | $19.7M | $99.0M | ||
| Q2 24 | $18.7M | $107.8M | ||
| Q1 24 | $16.3M | $118.3M |
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.12× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.4M | ||
| Q3 25 | $-1.3M | $-8.7M | ||
| Q2 25 | $-1.4M | $-7.5M | ||
| Q1 25 | $-3.5M | $-7.5M | ||
| Q4 24 | $-1.1M | $-24.0M | ||
| Q3 24 | $-591.6K | $765.0K | ||
| Q2 24 | $-803.1K | $-10.9M | ||
| Q1 24 | $-538.3K | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
